Scientists around the world are waiting for the University of Oxford to release the full details of a late-stage trial of the neocrown vaccine. Previous analyses have shown that the success rate of the trial is about 90%. This vaccine is just one of a growing number of new vaccines awaiting approval.
The vaccine uses adenovirus as the main vehicle to deliver the neo-crown virus’ spiny protein into human cells, which triggers the immune system to attack the virus. More than 20,000 volunteers in the United Kingdom and Brazil have participated in the vaccine trials, and so far no one has been hospitalized or seriously ill.
The Oxford vaccine is similar to the Russian Sputnik V vaccine, which has been tried on a small number of people, but experts believe the Oxford vaccine has fewer side effects.
The Oxford vaccine has a much lower dose and fewer side effects than the Satellite V vaccine,” says Peter Opshow of Imperial College London. The Russian vaccine uses a large dose of virus, which causes considerable short-term side effects, which may be acceptable in the current situation. The Oxford vaccine, however, uses a dose that minimizes side effects and produces a very strong immune response. So while the two are the same technology, there are very significant differences.”
Pfizer and Modena last week announced preliminary results from late-stage trials showing their vaccines to be nearly 95 percent effective. The two vaccines use completely different technologies than the Oxford vaccine.
Ian Jones, a virologist at the University of Reading, says, “This is only a tiny fraction of the neo-crown genome in messenger RNA, material that is completely chemically synthesized and can be checked by chemically relevant quality control methods, rather than the biologically relevant method of producing proteins in your own cells when injected, which can produce an immune response. “
Although mRNA vaccines have a high success rate, a major drawback is that they must be stored at ultra-low temperatures for the entire duration of the vaccine, which limits their distribution to the rest of the world. Also, the vaccine is expensive, ranging from $20 for Pfizer to $15 to $25 for Modena.
In contrast, the Oxford vaccine can be stored at refrigerated temperatures and is inexpensive. The vaccine’s manufacturing partner, AstraZeneca Pharmaceuticals, has set its price at around $2.50 and has pledged not to profit from the vaccine during a neo-crown pandemic.
Currently, AstraZeneca has put other product production on hold and expects to start supplying hundreds of millions of doses of the vaccine next January. Doctors and scientists are calling for more people to receive the new coronary vaccine.
Peter Upshaw said, “This is a very nasty virus. I think if people can realize the importance of vaccination and that there is solid science behind these vaccines and that they do work, it’s the only way out of the current dilemma that we have around the world.”
Recent Comments